NewAmsterdam Pharma (NAMS) Enterprise Value (2021 - 2026)
NewAmsterdam Pharma (NAMS) reported Enterprise Value of -$458.9 million for Q1 2026, up 43.23% on a YoY basis from -$320.4 million in Q1 2025, and up 6.59% sequentially from -$491.3 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Enterprise Value (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 6 years of Enterprise Value data on file, last reported at -$458.9 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 43.23% year-over-year to -$458.9 million; the trailing twelve-month figure through Mar 2026 stood at -$458.9 million (up 43.23% YoY), and the FY2025 full-year result was -$491.3 million, up 41.1% from the prior year.
- Enterprise Value advanced to -$458.9 million in Q1 2026, from -$491.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$340.4 million in Q4 2023 to a low of -$834.2 million in Q4 2024.
- A 5-year average of -$515.8 million and a median of -$453.2 million in 2026 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value plunged 636.6% in 2022 and surged 43.23% in 2026, its largest moves.
- Tracing NAMS's Enterprise Value over 5 years: stood at -$447.4 million in 2022, then increased by 23.9% to -$340.4 million in 2023, then slumped by 145.03% to -$834.2 million in 2024, then jumped by 41.1% to -$491.3 million in 2025, then increased by 6.59% to -$458.9 million in 2026.
- Business Quant data shows NAMS's Enterprise Value at -$458.9 million in Q1 2026, -$491.3 million in Q4 2025, and -$539.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | NewAmsterdam Pharma | 3.72 Bn | 3.72 Bn | - | -458.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -458.94 Mn |
| Dec 31, 2025 | -491.32 Mn |
| Sep 30, 2025 | -539.72 Mn |
| Jun 30, 2025 | -739.16 Mn |
| Mar 31, 2025 | -808.48 Mn |
| Dec 31, 2024 | -834.19 Mn |
| Sep 30, 2024 | -422.73 Mn |
| Jun 30, 2024 | -430.71 Mn |
| Mar 31, 2024 | -481.15 Mn |
| Dec 31, 2023 | -340.45 Mn |
| Sep 30, 2023 | -368.31 Mn |
| Jun 30, 2023 | -417.60 Mn |
| Mar 31, 2023 | -441.31 Mn |
| Dec 31, 2022 | -447.38 Mn |
| Dec 31, 2021 | -60.74 Mn |